Melanie Olesky, PhD, the head of medical affairs at Tetraphase, discusses a study presented at the 2019 annual MAD-ID (Making a Difference in Infectious Diseases) meeting. Xerava was effective in treating patients with complicated intra-abdominal infections with characteristics that are associated with poor outcomes. Read the article here.